Ascentage Pharma Group International (AAPG) Current Deferred Revenue (2023 - 2025)

Ascentage Pharma Group International (AAPG) has reported Current Deferred Revenue for 3 consecutive years, with $34.9 million the latest figure, recorded in Q4 2025.

• Quarterly Current Deferred Revenue rose 569.26% year-over-year to $34.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $34.9 million (up 569.26% YoY) and the FY2025 annual result came in at $35.4 million, up 589.81% from the prior year.
• Current Deferred Revenue rose to $34.9 million in Q4 2025 per AAPG's latest filing, from $5.2 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for AAPG reached as high as $40.2 million in Q4 2023 and fell as low as $5.2 million in Q4 2024.
• A 3-year average of $21.4 million and a median of $20.1 million in 2025 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue slumped 87.03% — and 2025, when it soared 569.26%.
• Year by year, Current Deferred Revenue stood at $40.2 million in 2023, then sank by 87.03% to $5.2 million in 2024, then surged by 569.26% to $34.9 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $34.9 million, $5.2 million, and $5.2 million for Q4 2025, Q2 2025, and Q4 2024 respectively.